Neovascular Age-Related Macular Degeneration (nAMD) – Market Access and Reimbursement Insights Report – 2026

Neovascular Age-Related Macular Degeneration (nAMD) Market Access and Reimbursement Insights

Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Access and Reimbursement Insights Report – 2026″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Neovascular Age-Related Macular Degeneration (nAMD) Overview

Neovascular age-related macular degeneration (nAMD) is an advanced, exudative variant of macular degeneration characterized by choroidal neovascularization, where pathological vessels sprout from the choriocapillaris into the subretinal space. Driven by vascular endothelial growth factor (VEGF) upregulation, these leaky vessels cause subretinal hemorrhage, macular fluid accumulation, and pigment epithelial detachment, leading to rapid, irreversible central vision loss. Diagnosis relies on optical coherence tomography displaying intraretinal or subretinal fluid, alongside fluorescein angiography to map neovascular architecture. In 2026, standard management centers on proactive, personalized treat-and-extend intravitreal anti-VEGF injection protocols. While traditional mono-targeted agents like aflibercept 2mg or biosimilars remain foundational, frontline regimens preferentially deploy longer-acting, next-generation therapeutics to minimize real-world treatment burden. These include faricimab, a bispecific antibody dual-targeting VEGF-A and angiopoietin-2 to optimize vascular stability, and high-dose aflibercept 8mg, which utilizes structural pharmacokinetic intensification to safely extend standard maintenance dosing intervals up to sixteen weeks. Early detection, strict compliance tracking, and lifestyle optimization are mandatory to preserve long-term functional autonomy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Neovascular Age-Related Macular Degeneration (nAMD) – Market Access and Reimbursement Insights Report – 2026